Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537413 | 0.88 | GAA (0.60) | ALDH1A1GAAMAPTALOX15 | |
| SCHEMBL4292565 | 0.87 | NPSR1 (0.59) | ALDH1A1GAAMAPTALOX15SMN1; SMN2 | |
| SCHEMBL5563711 | 0.80 | SMN1; SMN2 (0.72) | CHEK1ALDH1A1GAAMAPTPLA2G1B | |
| SCHEMBL1646808 | 0.78 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL7537046 | 0.76 | CHEK1 (0.54) | CHEK1MAPT | |
| SCHEMBL1646812 | 0.74 | NPSR1 (0.51) | CHEK1GAAMAPT | |
| SCHEMBL5343204 | 0.73 | CHEK1 (0.59) | CHEK1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5558994 | 0.73 | POLB (0.66) | CHEK1ALDH1A1GAAMAPT | |
| SCHEMBL7833448 | 0.73 | CHEK1 (0.50) | CHEK1GAASMN1; SMN2 | |
| SCHEMBL14356002 | 0.73 | CHEK1 (0.54) | CHEK1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | claimed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | disclosed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | ATR, ATM, CHEK1 | CHEK1 3/4885ALDH1A1 4053/4885GAA 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.